Just a gut feeling: Faecal microbiota transplant for treatment of depression - A mini-review.

IF 4.5 3区 医学 Q1 CLINICAL NEUROLOGY
Journal of Psychopharmacology Pub Date : 2024-04-01 Epub Date: 2024-03-26 DOI:10.1177/02698811241240308
Minna Chang, Kai Tuomas Chang, Fuju Chang
{"title":"Just a gut feeling: Faecal microbiota transplant for treatment of depression - A mini-review.","authors":"Minna Chang, Kai Tuomas Chang, Fuju Chang","doi":"10.1177/02698811241240308","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The microbiota-gut-brain axis (MGBA) allows bidirectional crosstalk between the brain and gut microbiota (GM) and is believed to contribute to regulating mood/cognition/behaviour/metabolism/health and homeostasis. Manipulation of GM through faecal microbiota transplant (FMT) is a new, exciting and promising treatment for major depressive disorder (MDD).</p><p><strong>Aims: </strong>This mini-review examines current research into GM and FMT as a therapy for depression.</p><p><strong>Methods: </strong>Original research articles published in Medline/Cochrane Library/PubMed/EMBASE/PsycINFO databases/National Institute of Health website Clinicaltrials.gov/controlled-trials.com were searched. Full articles included in reference lists were evaluated. We summarise current data on GM and depression and discuss communication through the MGBA and the interaction of antidepressants and GM through this. We review compositions of dysbiosis in depressed cohorts, focusing on future directions in the treatment of MDD.</p><p><strong>Results: </strong>Studies have demonstrated significant gut dysbiosis in depressed patients compared to healthy cohorts, with overgrowth of pro-inflammatory microbiota, reduction in anti-inflammatory species and reduced overall stability and taxonomic richness. FMT allows the introduction of healthy microbiota into the gastrointestinal tract, facilitating the restoration of eubiosis.</p><p><strong>Conclusion: </strong>The GM plays an integral role in human health and disease through its communication with the rest of the body via the MGBA. FMT may provide a means to transfer the healthy phenotype into the recipient and this concept in humans is attracting enormous attention as a prospective treatment for psychopathologies, such as MDD, in the future. It may be possible to manipulate the GM in a number of ways, but further research is needed to determine the exact likelihood and profiles involved in the development and amelioration of MDD in humans, as well as the long-term effects and potential risks of this procedure.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"353-361"},"PeriodicalIF":4.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811241240308","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The microbiota-gut-brain axis (MGBA) allows bidirectional crosstalk between the brain and gut microbiota (GM) and is believed to contribute to regulating mood/cognition/behaviour/metabolism/health and homeostasis. Manipulation of GM through faecal microbiota transplant (FMT) is a new, exciting and promising treatment for major depressive disorder (MDD).

Aims: This mini-review examines current research into GM and FMT as a therapy for depression.

Methods: Original research articles published in Medline/Cochrane Library/PubMed/EMBASE/PsycINFO databases/National Institute of Health website Clinicaltrials.gov/controlled-trials.com were searched. Full articles included in reference lists were evaluated. We summarise current data on GM and depression and discuss communication through the MGBA and the interaction of antidepressants and GM through this. We review compositions of dysbiosis in depressed cohorts, focusing on future directions in the treatment of MDD.

Results: Studies have demonstrated significant gut dysbiosis in depressed patients compared to healthy cohorts, with overgrowth of pro-inflammatory microbiota, reduction in anti-inflammatory species and reduced overall stability and taxonomic richness. FMT allows the introduction of healthy microbiota into the gastrointestinal tract, facilitating the restoration of eubiosis.

Conclusion: The GM plays an integral role in human health and disease through its communication with the rest of the body via the MGBA. FMT may provide a means to transfer the healthy phenotype into the recipient and this concept in humans is attracting enormous attention as a prospective treatment for psychopathologies, such as MDD, in the future. It may be possible to manipulate the GM in a number of ways, but further research is needed to determine the exact likelihood and profiles involved in the development and amelioration of MDD in humans, as well as the long-term effects and potential risks of this procedure.

只是一种直觉粪便微生物群移植治疗抑郁症--微型综述。
背景:微生物群-肠道-大脑轴(MGBA)允许大脑和肠道微生物群(GM)之间进行双向交流,并被认为有助于调节情绪/认知/行为/代谢/健康和体内平衡。通过粪便微生物群移植(FMT)来控制肠道微生物群是治疗重度抑郁症(MDD)的一种新的、令人兴奋且前景广阔的疗法:方法:检索发表在 Medline/Cochrane Library/PubMed/EMBASE/PsycINFO 数据库/美国国家卫生研究院网站 Clinicaltrials.gov/controlled-trials.com 上的原始研究文章。对参考文献列表中的完整文章进行了评估。我们总结了目前有关转基因与抑郁症的数据,并讨论了通过 MGBA 进行的交流,以及抗抑郁药物与转基因之间的相互作用。我们回顾了抑郁症人群中菌群失调的构成,重点关注治疗 MDD 的未来方向:研究表明,与健康人群相比,抑郁症患者肠道菌群失调严重,促炎微生物群过度生长,抗炎物种减少,整体稳定性和分类丰富度降低。FMT可以将健康的微生物群引入胃肠道,促进优生的恢复:结论:通过与身体其他部分的沟通,胃肠道微生物群在人类健康和疾病中发挥着不可或缺的作用。FMT可以提供一种将健康表型转移到受体的方法,而这一概念在人类身上作为未来治疗精神病症(如MDD)的一种方法,正引起人们的极大关注。也许有可能以多种方式操纵基因改造,但还需要进一步研究,以确定在人类 MDD 的发展和改善过程中涉及的确切可能性和特征,以及这一过程的长期影响和潜在风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Psychopharmacology
Journal of Psychopharmacology 医学-精神病学
CiteScore
8.60
自引率
4.90%
发文量
126
审稿时长
3-8 weeks
期刊介绍: The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信